No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2009, Pages 81-87

  Mueller, Silke C ^a   Majcher Peszynska, Jolanta ^a   Mundkowski, Ralf G ^a   Uehleke, Bernhard ^b   Klammt, Sebastian ^a   Sievers, Hartwig ^d   Lehnfeld, Romanus ^d   Frank, Bruno ^c   Thurow, Kerstin ^a   Kundt, Guenther ^a   Drewelow, Bernd ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Kneipp Werke   (Germany)

^d PhytoLab GmbH   (Germany)

Author keywords

CYP3A; Drug interaction; Hyperforin; Hypericum

Indexed keywords

CYTOCHROME P450 3A; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; MIDAZOLAM; MIDAZOLAM MALEATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; ENZYME INDUCTION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; BICYCLO COMPOUNDS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; MALE; MIDAZOLAM; PHLOROGLUCINOL; PLANT PREPARATIONS; POWDERS; SUBSTRATE SPECIFICITY; TERPENES; YOUNG ADULT;

EID: 57849117383     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0554-y     Document Type: Article

References (31)

1. V Butterweck 2003 Mechanism of action of St. John's wort in depression-what is known? CNS Drugs 17 539 562
2. V Butterweck M Schmidt 2007 St. John's wort: role of active compounds for its mechanism of action and efficacy Wien Med Wochenschr 157 356 361
3. P Zanoli 2004 Role of hyperforin in the pharmacological activities of St. John's wort CNS Drug Rev 10 203 218
4. V Butterweck A Nahrstedt J Evans S Hufeisen L Rauser J Savage B Popadak P Ernsberger BL Roth 2002 In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs Psychopharmacology 162 193 202
5. M Melzer D Fuhrken R Kolkmann 1998 Hyperforin im Johanniskraut - Hauptwirkstoff oder nur Leitsubstanz? Dtsch Apoth Ztg 138 56 62
6. R Madabushi B Frank B Drewelow H Derendorf V Butterweck 2006 Hyperforin in St. John's wort drug interactions Eur J Clin Pharmacol 62 225 233
7. GC De los Reyes RT Koda 2002 Determining hyperforin and hypericin content in eight brands of St. John's wort Am J Health Syst Pharm 59 545 547
8. AH Draves SE Walker 2003 Analysis of the hypericin and pseudohypericin content of commercially available St. John's wort preparations Can J Clin Pharmacol 10 114 118
9. M Wurglics K Westerhoff A Kaunzinger A Wilke A Baumeister J Dressman M Schubert-Zsilavecz 2001 Comparison of German St. John's wort products according to hyperforin and total hypericin content J Am Pharm Assoc 41 560 566
10. E Schrader 2000 Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression Int Clin Psychopharmacol 15 61 68
11. H Woelk 2001 Comparison of St. John's wort and imipramine for treating depression: a randomised controlled trial BMJ 321 536 539
12. DL Whitten SP Myers JA Hawrelak H Wohlmuth 2006 The effect of St. John's wort extracts on CYP3A: a systematic review of prospective clinical trials Br J Clin Pharmacol 62 512 526
13. M Mannel 2004 Drug interactions with St. John's wort - mechanisms and clinical implications Drug Saf 27 773 797
14. D Dürr B Stieger GA Kullak-Ublick KM Rentsch HC Steinert PJ Meier K Fattinger 2000 St. John's wort induces intestinal p-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin Pharmacol Ther 68 598 604
15. LB Moore B Goodwin SA Jones GB Wisely CJ Serabjit-Singh TM Willson JL Collins SA Kliewer 2000 St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc Natl Acad Sci USA 97 7500 7502
16. JM Wentworth M Agostini J Love JW Schwabe VKK Chatterjee 2000 St. John's wort, a herbal antidepressant, activates the steroid X receptor J Endocrinol 166 R11 R16
17. U Gödtel-Armbrust A Metzger U Kroll O Kelber L Wojnowski 2007 Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort Naunyn Schmiedberg's Arch Pharmacol 375 377 382
18. BJ Komoroski S Zhang H Cai JM Hutzler R Frye TS Tracy SC Strom T Lehmann CYW Ang YY Cui R Venkataramanan 2004 Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures Drug Metab Dis 32 512 518
19. SC Mueller J Majcher-Peszynska B Uehleke S Klammt RG Mundkowski W Miekisch H Sievers S Bauer B Frank G Kundt B Drewelow 2006 The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose Eur J Clin Pharmacol 62 29 36
20. I Mai S Bauer ES Perloff A Johne B Uehleke B Frank K Budde I Roots 2004 Hyperforin content determines the magnitude of the St. John's wort - cyclosporine drug interaction Clin Pharmacol Ther 76 330 340
21. G Arold F Donath A Maurer K Diefenbach S Bauer HH Henneicke von Zepelin M Friede I Roots 2005 No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract Planta Med 71 331 337
22. SM Huang R Temple DC Throckmorton LJ Lesko 2007 Drug interaction studies: study design, data analysis, and implications for dosing and labeling Clin Pharmacol Ther 81 298 304
23. F Gaedcke 1997 Johanniskraut und dessen Zubereitungen Dtsch Apoth Ztg 137 3753 3757
24. J Hölzl E Ostrowski 1987 Johanniskraut (Hypericum perforatum): HPLC-Analyse der wichtigen Inhaltsstoffe und deren Variabilität in einer Population Dtsch Apoth Ztg 127 1227 1230
25. W Miekisch P Fuchs A Berg G Nöldge-Schomburg B Drewelow R Mundkowski 2003 An improved GC/MS method for the determination of midazolam in human plasma Int J Clin Pharmacol Ther 4 560
26. U.S. Food and Drug Administration (2001) Guidance for industry - bioanalytical method validation. http://www.fda.gov/CDER/GUIDANCE/4252fnl.htm. Accessed 15 August 2008
27. U.S. Food and Drug Administration (1994) Reviewer guidance - validation of chromatographic methods. http://www.fda.gov/CDER/GUIDANCE/cmc3.pdf. Accessed 15 August 2008
28. BJ Ring BE Patterson MI Mitchell M Vandenbranden J Gillespie AW Bedding H Jewell CD Payne ST Forgue J Ecksetin SA Wrighton DL Phillips 2005 Effect of tadalafil on cytochrome P450 3A4 - mediated clearance: studies in vitro and in vivo Clin Pharmacol Ther 77 63 75
29. BM Johnson IH Song KK Adkison J Borland L Fang Y Lou MM Berrey AN Nafziger SC Piscitelli JS Bertino 2006 Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail J Clin Pharmacol 46 577 587
30. Z Wang C Gorski MA Hamman S-M Huang LJ Lesko SD Hall 2001 The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin Pharmacol Ther 70 317 326
31. GK Dresser UI Schwarz GR Wilkinson RB Kim 2003 Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects Clin Pharmacol Ther 73 41 50